Because semaglutide often leads to significant weight loss and improved metabolic function, fertility specialists are increasingly observing changes in reproductive patterns among patients using these medications
Il farmaco oggi pi atteso il retatrutide , un agonista che agisce contemporaneamente su tre recettori ormonali (GIP, GLP-1 e glucagone) e che nel primo studio di fase 3 pubblicato TRIUMPH-4, dati topline di dicembre 2025 ancora in attesa di pubblicazione peer-reviewed ha fatto registrare una perdita di peso media del 28,7% a 68 settimane, la pi alta mai ottenuta in un trial registrativo per lobesit (Lilly, 2025)
The absence of visible changes does not guarantee medication integrity after freezing exposure
Tirzepatide was initially approved for type 2 diabetes (Mounjaro), and it is now also approved for long-term weight loss in adults with obesity or overweight with weight-related health conditions (Zepbound)
This field should initiate the collaboration of endocrinologists, diabteologists, ENT specialists, neuroscientists and nutritionists to further explore the role of GLP-1 in taste perception